<DOC>
	<DOCNO>NCT01106690</DOCNO>
	<brief_summary>The purpose study evaluate efficacy safety 2 different dos canagliflozin compare placebo patient type 2 diabetes mellitus receving treatment metformin pioglitazone inadequate glycemic ( blood sugar ) control .</brief_summary>
	<brief_title>The CANTATA-MP Trial ( CANagliflozin Treatment Trial Analysis - Metformin Pioglitazone )</brief_title>
	<detailed_description>Canagliflozin drug test see may useful treat patient diagnose type 2 diabetes mellitus ( T2DM ) . This randomize ( study drug assign chance ) , double-blind ( neither patient study doctor know name assign treatment ) , parallel-group , 3-arm ( 3 treatment group ) multicenter study determine efficacy , safety , tolerability canagliflozin ( 100 mg 300 mg ) compare placebo ( capsule look like treatment real medicine ) patient T2DM achieve adequate response current antihyperglycemic therapy metformin pioglitazone control diabetes . Approximately 360 patient T2DM receive combination therapy metformin pioglitazone receive addition once-daily treatment canagliflozin ( 100 mg 300 mg ) placebo capsule 26 week follow 26-week extension period patient treat canagliflozin ( 100 mg 300 mg ) continue treatment additional 26 week patient treat placebo switch active double-blind treatment sitagliptin 100 mg , antihyperglycemic agent administer once-daily 26 week . In addition , patient take protocol specify stable dos metformin pioglitazone along assign study drug duration study . Patients participate study approximately 59 78 week . During study , patient 's fasting blood sugar remain high despite treatment study drug , patient receive treatment glimepiride ( rescue therapy ) accordance local prescribe information . During treatment , patient monitor safety review adverse event , result laboratory test , 12-lead electrocardiogram ( ECGs ) , vital sign measurement , body weight , physical examination , self-monitored blood glucose ( SMGB ) measurement . The primary outcome measure study effect canagliflozin relative placebo hemoglobin A1c ( HbA1c ) 26 week treatment . Study drug take orally ( mouth ) daily first meal day unless otherwise specify . Patients take single-blind placebo capsule 2 week randomization . After randomization , patient take double-blind canagliflozin ( 100 mg 300 mg ) 52 week OR placebo 26 week switch double-blind sitagliptin 100 mg 26 week .</detailed_description>
	<mesh_term>Diabetes Mellitus</mesh_term>
	<mesh_term>Diabetes Mellitus , Type 2</mesh_term>
	<mesh_term>Pioglitazone</mesh_term>
	<mesh_term>Metformin</mesh_term>
	<mesh_term>Canagliflozin</mesh_term>
	<mesh_term>Sitagliptin Phosphate</mesh_term>
	<criteria>All patient must diagnosis T2DM currently treat PPAR gamma agent ( ( pioglitazone rosiglitazone ) another antidiabetes agent ( metformin ) Patients study must HbA1c &gt; =7 &lt; =10.5 % fast plasma glucose ( FPG ) &lt; 270 mg/dL ( 15 mmol/L ) History diabetic ketoacidosis , type 1 diabetes mellitus ( T1DM ) , pancreas beta cell transplantation , diabetes secondary pancreatitis pancreatectomy severe hypoglycemic episode within 6 month screen</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>80 Years</maximum_age>
	<verification_date>June 2013</verification_date>
	<keyword>Canagliflozin</keyword>
	<keyword>Placebo</keyword>
	<keyword>Sitagliptin ( Januvia )</keyword>
	<keyword>Metformin</keyword>
	<keyword>Pioglitazone ( Actos )</keyword>
	<keyword>Hemoglobin A1c</keyword>
	<keyword>Type 2 diabetes mellitus</keyword>
</DOC>